Jun 2026 (Q2 FY26) — Aug 4, 2026
Ultragenyx Q2 FY26 — Strong Commercial Performance and Key Pipeline Catalysts Ahead
Read the full callUltragenyx (RARE) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Ultragenyx earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 214 | +28.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -35.0 | +29.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -92.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$14.54 −4.15% · −$0.63
Performance −56.5% 1Y
1Y: $33.43 on 15 Oct 2025 → $14.54. High $36.54 (4 Dec 2025), low $12.88 (16 Sept 2026).
- Previous close
- $15.17
- 52-week range
- $12.88 – $36.54
- One year
- −57.20%
Overview
- Symbol
- RARE
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Ultragenyx earnings calls (RARE)
Financials
What the filings say
Net profit, year on year: +20% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 139 | 165 | 139 | 167 | 160 | 207 | 136 | 214 |
| Operating profit | -132 | -122 | -143 | -108 | -171 | -113 | -169 | -75 |
| Operating margin | −94.6% | −74.2% | −102.9% | −64.7% | −106.8% | −54.6% | −124.3% | −35.0% |
| Profit before tax | -133 | -133 | -150 | -114 | -180 | -128 | -184 | -91 |
| Tax rate | −0.2% | 0.0% | −0.7% | −0.9% | −0.5% | −0.7% | −0.5% | −1.1% |
| Net profit | -134 | -133 | -151 | -115 | -180 | -129 | -185 | -92 |
| EPS ($ per share) | -1.40 | — | -1.57 | -1.17 | -1.81 | — | -1.84 | -0.90 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,030 | -1,433 | -1,620 | -2,074 | -2,781 | -3,388 | -3,957 | -4,532 |
| Total liabilities | 111 | 482 | 605 | 600 | 1,193 | 1,216 | 1,241 | 1,605 |
| Fixed assets | 20 | 44 | 74 | 141 | 260 | 291 | 266 | 244 |
| Investments | 346 | 322 | — | — | — | — | — | — |
| Total assets | 720 | 1,135 | 1,760 | 1,522 | 1,545 | 1,491 | 1,503 | 1,532 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -291 | -345 | -132 | -339 | -380 | -475 | -414 | -466 |
| Cash from investing | -33 | -13 | -179 | -195 | -292 | 168 | -18 | 236 |
| Cash from financing | 337 | 679 | 600 | 119 | 501 | 388 | 399 | 478 |
| Net cash flow | 12 | 321 | 290 | -417 | -172 | 81 | -35 | 252 |
| Capital expenditure | -4 | -25 | -44 | -73 | -116 | -44 | -7 | -6 |
| Free cash flow | -295 | -370 | -176 | -412 | -497 | -519 | -421 | -472 |
Insider filings
51 filings between Dec 10, 2025 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$3.70M
27 sales by 9 insiders
56% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 22
- Award — granted as compensation
- 2
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| KAKKIS EMIL D | — | $1.24M | Mar 2, 2026 |
| Horn Howard | — | $1.08M | Aug 3, 2026 |
| Parschauer Karah Herdman | — | $487.9K | Aug 3, 2026 |
| Harris Erik | — | $240.3K | Mar 2, 2026 |
| Pinion John Richard | — | $228.7K | Mar 2, 2026 |
| Crombez Eric | — | $168.8K | May 5, 2026 |
| SULIMAN SHEHNAAZ | — | $144.2K | May 18, 2026 |
| Huizenga Theodore Alan | — | $59.8K | Sep 15, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale 10b5-1 plan | 1,283 | $17.4K |
| Sep 3, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | 161 | $2.3K |
| Aug 3, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 4,696 | $117.0K |
| Aug 3, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale 10b5-1 plan | 1,900 | $47.3K |
| Jul 1, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 4,698 | $155.6K |
| Jun 15, 2026 | Sanders Corazon (Corsee) D. Director | Sale | 2,000 | $50.1K |
| Jun 15, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale 10b5-1 plan | 1,899 | $46.8K |
| Jun 1, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 4,653 | $110.6K |
| May 18, 2026 | SULIMAN SHEHNAAZ Director | Sale 10b5-1 plan | 5,740 | $144.2K |
| May 14, 2026 | Fust Matthew K Director | Award | 7,751 | $0 |
| May 14, 2026 | SULIMAN SHEHNAAZ Director | Award 10b5-1 plan | 7,751 | $0 |
| May 14, 2026 | Sanders Corazon (Corsee) D. Director | Award | 7,751 | $0 |
| May 14, 2026 | Ray Amrit Director | Award | 7,751 | $0 |
| May 14, 2026 | WELCH DANIEL G Director | Award | 7,751 | $0 |
| May 14, 2026 | NARACHI MICHAEL Director | Award | 7,751 | $0 |
| May 14, 2026 | Dunsire Deborah Director | Award | 7,751 | $0 |
| May 5, 2026 | Crombez Eric EVP and Chief Medical Officer | Sale | 344 | $8.6K |
| May 1, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 4,683 | $116.6K |
| Apr 22, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Award | 20,241 | $0 |
| Apr 16, 2026 | Horn Howard Chief Financial Officer | Award | 34,674 | $0 |
| Apr 16, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Award | 28,895 | $0 |
| Apr 16, 2026 | Pinion John Richard See Remarks | Award | 23,116 | $0 |
| Apr 16, 2026 | Huang Dennis Karl See Remarks | Award | 23,116 | $0 |
| Apr 16, 2026 | KAKKIS EMIL D President & CEO | Award | 76,745 | $0 |
| Apr 16, 2026 | Crombez Eric EVP and Chief Medical Officer | Award | 34,674 | $0 |
| Apr 16, 2026 | Harris Erik EVP & Chief Commercial Officer | Award | 28,895 | $0 |
| Apr 1, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 4,683 | $98.2K |
| Mar 10, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | 3,508 | $79.5K |
| Mar 6, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | 6,018 | $128.8K |
| Mar 3, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 1,635 | $36.6K |
| Mar 2, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 3,119 | $70.3K |
| Mar 2, 2026 | Harris Erik EVP & Chief Commercial Officer | Sale | 10,539 | $240.3K |
| Mar 2, 2026 | Pinion John Richard See Remarks | Sale | 10,029 | $228.7K |
| Mar 2, 2026 | Huang Dennis Karl See Remarks | Tax withheld | 999 | $23.4K |
| Mar 2, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Tax withheld | 148 | $3.5K |
| Mar 2, 2026 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | 1,632 | $37.2K |
| Mar 2, 2026 | Crombez Eric EVP and Chief Medical Officer | Sale | 7,029 | $160.3K |
| Mar 2, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Sale | 8,135 | $185.5K |
| Mar 2, 2026 | KAKKIS EMIL D President & CEO | Sale | 54,404 | $1.24M |
| Mar 2, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 5,290 | $120.6K |
| Mar 1, 2026 | Huang Dennis Karl See Remarks | Award | 11,137 | $0 |
| Mar 1, 2026 | Horn Howard Chief Financial Officer | Award 10b5-1 plan | 6,143 | $0 |
| Mar 1, 2026 | Parschauer Karah Herdman EVP and Chief Legal Officer | Award | 11,137 | $0 |
| Mar 1, 2026 | KAKKIS EMIL D President & CEO | Award | 71,177 | $0 |
| Mar 1, 2026 | Harris Erik EVP & Chief Commercial Officer | Award | 11,643 | $0 |
| Mar 1, 2026 | Pinion John Richard See Remarks | Award | 11,137 | $0 |
| Mar 1, 2026 | Crombez Eric EVP and Chief Medical Officer | Award | 11,643 | $0 |
| Feb 2, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 3,061 | $72.1K |
| Jan 2, 2026 | Horn Howard Chief Financial Officer | Sale 10b5-1 plan | 3,150 | $71.9K |
| Dec 29, 2025 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | 85 | $2.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Ultragenyx Pharmaceutical Inc.
Free account. Everything above stays public.
Write why you follow Ultragenyx Pharmaceutical Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading